You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Current Oncology
Download PDF
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
  • Case Report
  • Open Access

1 October 2010

Complete Response of Hepatocellular Carcinoma with Sorafenib and 90y Radioembolization

,
,
,
,
,
,
,
,
and
1
Department of Surgery, McGill University, and Hepatopancreatobiliary and Transplant Surgery Program, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada
2
Department of Medical Oncology, McGill University Health Centre, Montreal, QC, Canada
3
Department of Radiology, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol.2010, 17(5), 67-69;https://doi.org/10.3747/co.v17i5.609
Version Notes
Order Reprints

Abstract

Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-year-old man that achieved a pathologic complete response and was made amenable to surgery with sorafenib in combination with 90Y radioembolization. The patient’s survival was more than double the median for patients treated with sorafenib alone.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Primary Central Nervous System T-Cell Lymphoma in Aids Patients: Case Report and Literature Review
Previous
A Rare Adverse Skin Reaction after 8 Gy of Radiation Therapy to the Thoracic Spine: Case Report and Review of the Literature
Next